secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2025-08-15T23:59:59+00:00
Accession:  0001437749-25-027059
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA Fast Track for NRX-100 in suicidal depression; ANDA filing deficiency noted
-------------------------------------------------------------------------------

- FDA Fast Track designation for NRX-100 (IV ketamine) to treat suicidal ideation in depression, including bipolar depression.
- Addressable population expands to 13M Americans considering suicide/year, 10x larger than prior 2017 designation.
- Company also received FDA letter on August 13 citing missing batch records and 6% inactive ingredient difference in ANDA for NRX-100; expects to remedy and resubmit.
- Fast Track enables potential CNPV/accelerated approval, rolling review, and enhanced FDA communication.
- NRX-100 is preservative-free ketamine; company citizen petition to remove BZT from IV ketamine products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925027059/0001437749-25-027059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925027059/nrxp20250814_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-027059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer